Last update Oct. 20, 2023

G02CB04

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Quinagolide is a dopamine D2 agonist other than ergot that has actions and uses similar to those of bromocriptine. It has been used in the treatment of disorders associated with hyperprolactinemia and to inhibit lactation. Oral administration once daily.

At the date of the last update we found no published data on its excretion in breast milk.

Its pharmacokinetic data (high binding to plasma proteins and very large volume of distribution) make it unlikely to pass into breast milk in clinically significant quantities.

Its low oral bioavailability makes it difficult for it to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period in which there may be greater intestinal permeability.

As a dopaminergic agonist, it reduces prolactin secretion and may suppress breastfeeding. (van der Heijden 1991, Kremer 1990)  


See below the information of this related product:

  • Hypergalactia; Hyperlactation (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

We do not have alternatives for G02CB04.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

G02CB04 is Quinagolide Hydrochloride in ATC Code/s.

Is written in other languages:

Group

G02CB04 belongs to this group or family:

Tradenames

Main tradenames from several countries containing G02CB04 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 4 %
Molecular weight 432 daltons
Protein Binding 90 %
VD 1.43 l/Kg
pKa 10.2 -
Tmax 0.5 - 1 hours
T½ 11.5 - 17 hours

References

  1. [No authors listed] Do not use drugs to prevent onset of lactation. Relieve the discomfort and wait. Prescrire Int. 2013 Abstract
  2. van der Heijden PF, Kremer JA, Brownell J, Rolland R. Lactation inhibition by the dopamine agonist CV 205-502. Br J Obstet Gynaecol. 1991 Mar;98(3):270-6. Abstract
  3. Kremer JA, van der Heijden PF, Schellekens LA, Thomas CM, Brownell J, Rolland R. Postpartum return of pituitary and ovarian activity during lactation inhibition with the new dopamine agonist CV 205-502 and during normal lactation. Acta Endocrinol (Copenh). 1990 Jun;122(6):759-65. Abstract

Total visits

209

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM